BERLIN (AP) — German pharmaceutical company Merck KgaA says a late stage trial of a new lung cancer drug has failed to meet expectations.
The company, based in Darmstadt, says the drug Stimuvax did not improve the overall survival of patients in the phase III study.
Merck shares fell 3.1 percent to €98.20 ($129.41) after the announcement early Wednesday.
The company is a separate entity from Merck & Co., which is based in the U.S.
CRYING! This 4-letter word newspaper caption oops has us in stitches!
The truth about gun deaths: numbers and actual solutions
Ben Carson Is Right On Jews, Guns, And Nazis - Bearing Arms - Ben Carson, Holocaust, Nazis
Here's Trey Gowdy's Scathing Letter to Democrat Elijah Cummings
Paul Ryan is a Dangerous Pick for Conservatives | RedState
- Vladimir Putin’s Russia Adopts Concealed Carry
The Problem Isn't Guns Or White Men | Human Events